BEW
BMRN icon

Burton Enright Welch’s BioMarin Pharmaceuticals BMRN Stock Holding History

Burton Enright Welch’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,675
Closed -$202K – 132
2025
Q2 		$202K Buy
3,675
+1
+0% +$59 0.04% 119
2025
Q1 		$260K Sell
3,674
-9
-0.2% -$605 0.05% 95
2024
Q4 		$242K Sell
3,683
-2
-0.1% -$134 0.05% 89
2024
Q3 		$259K Sell
3,685
-39
-1% -$3.26K 0.06% 81
2024
Q2 		$307K Hold
3,724
– – 0.07% 80
2024
Q1 		$325K Sell
3,724
-1
-0% -$90 0.08% 73
2023
Q4 		$359K Buy
3,725
+39
+1% +$3.45K 0.1% 67
2023
Q3 		$326K Sell
3,686
-130
-3% -$11.6K 0.1% 62
2023
Q2 		$331K Sell
3,816
-235
-6% -$22.1K 0.1% 58
2023
Q1 		$394K Sell
4,051
-27
-0.7% -$2.8K 0.15% 53
2022
Q4 		$422K Sell
4,078
-2,906
-42% -$273K 0.18% 45
2022
Q3 		$592K Buy
6,984
+323
+5% +$28.8K 0.29% 35
2022
Q2 		$552K Buy
6,661
+3
+0% +$239 0.33% 33
2022
Q1 		$513K Sell
6,658
-4,575
-41% -$383K 0.28% 40
2021
Q4 		$992K Buy
+11,233
New +$927K 0.66% 20

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Burton Enright Welch's BMRN Position: Q3 2025 in Review

Burton Enright Welch sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 3,675 shares — an estimated $202K sold.

Burton Enright Welch first reported a position in BMRN in Q4 2021 and held it in 15 quarters. The position peaked at $992K in Q4 2021. 577 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • Burton Enright Welch reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Burton Enright Welch sold 3,675 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $202K.
  • Burton Enright Welch first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 15 quarters.
  • Burton Enright Welch's BioMarin Pharmaceuticals position peaked at $992K in Q4 2021.
  • 577 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Burton Enright Welch's 13F filing for Q3 2025, filed 9 Mar 2026.